Cargando…
Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to...
Autores principales: | Chung, Jung Wha, Choi, Hwa Young, Ki, Moran, Jang, Eun Sun, Jeong, Sook-Hyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960981/ https://www.ncbi.nlm.nih.gov/pubmed/32616682 http://dx.doi.org/10.5009/gnl19387 |
Ejemplares similares
-
Current status of hepatitis C virus infection and countermeasures in South Korea
por: Jeong, Sook-Hyang, et al.
Publicado: (2017) -
Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data
por: Ki, Moran, et al.
Publicado: (2017) -
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
por: Jang, Eun Sun, et al.
Publicado: (2021) -
Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea
por: Kim, Bo Hyun, et al.
Publicado: (2017) -
Nationwide Seropositivity of Hepatitis A in Republic of Korea from 2005 to 2014, before and after the Outbreak Peak in 2009
por: Kim, Kyung-Ah, et al.
Publicado: (2017)